CIK 0001321834 · Non-accelerated filer<br>Smaller reporting company
Q/C TECHNOLOGIES, INC.
Sign in to watch- Ticker
- QCLS
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 856-848-8698
- Business address
- 1185 AVENUE OF THE AMERICAS, SUITE 249, NEW YORK, NY, 10036
- Former names
- Q/C TECHNOLOGIES, INC., TNF Pharmaceuticals, Inc., MyMD Pharmaceuticals, Inc., Akers Biosciences, Inc., Akers Biosciences Inc
- DEF 14A Proxy Proxy Statement
- 3 Insider Initial Statement of Ownership
- UPLOAD Other SEC-generated Letter
- 8-K Event Shareholder rights changed · Bylaws or fiscal year change
- S-3 Offering Registration Statement
- 8-K/A Event Material agreement
- PRE 14A Proxy Proxy Statement (Preliminary)
- 8-K Event Material agreement · Shareholder rights changed · Executive or director change · Bylaws or fiscal year change · Other events
- D Other Notice of Sales of Unregistered Securities
- D Other Notice of Sales of Unregistered Securities
- 3 Insider Initial Statement of Ownership
- SC 13D Stake Beneficial Ownership Report
- 8-K Event Shareholder rights changed · Bylaws or fiscal year change · Other events
- 8-K Event Material agreement · Unregistered share sale · Shareholder rights changed · Bylaws or fiscal year change · Other events
- 3 Insider Initial Statement of Ownership
- 10-Q Report Quarterly Report
- 8-K Event Executive or director change
- 8-K Event Material agreement · Shareholder rights changed · Executive or director change · Bylaws or fiscal year change
- 10-K Report Annual Report
- 8-K/A Event Bylaws or fiscal year change
Page 6 of 31 · 604 filings